NeuroBo Pharmaceuticals (NASDAQ:NRBO) versus Jazz Pharmaceuticals (NASDAQ:JAZZ) Financial Survey

NeuroBo Pharmaceuticals (NASDAQ:NRBO) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.

Valuation and Earnings

This table compares NeuroBo Pharmaceuticals and Jazz Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroBo Pharmaceuticals	N/A	N/A	-$12.47 million	N/A	N/A
Jazz Pharmaceuticals	$3.84 billion	1.75	$414.83 million	$4.85	22.01

Jazz Pharmaceuticals has higher revenue and earnings than NeuroBo Pharmaceuticals.

Insider & Institutional Ownership

1.4% of NeuroBo Pharmaceuticals shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 0.5% of NeuroBo Pharmaceuticals shares are owned by company insiders. Comparatively, 4.2% of Jazz Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares NeuroBo Pharmaceuticals and Jazz Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeuroBo Pharmaceuticals	N/A	-90.22%	-69.52%
Jazz Pharmaceuticals	8.61%	27.86%	8.91%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for NeuroBo Pharmaceuticals and Jazz Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroBo Pharmaceuticals	0	0	1	0	3.00
Jazz Pharmaceuticals	0	2	12	0	2.86

NeuroBo Pharmaceuticals presently has a consensus price target of $10.00, indicating a potential upside of 106.61%. Jazz Pharmaceuticals has a consensus price target of $190.00, indicating a potential upside of 78.02%. Given NeuroBo Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts plainly believe NeuroBo Pharmaceuticals is more favorable than Jazz Pharmaceuticals.

Risk & Volatility

NeuroBo Pharmaceuticals has a beta of -0.3, suggesting that its stock price is 130% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500.

Summary

Jazz Pharmaceuticals beats NeuroBo Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

About NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.